You are here: Home » Current Affairs » Coronavirus » News
Business Standard

AstraZeneca partner sticks with 2 full dose regimen in India Covid trials

The British drugmaker has said its COVID-19 vaccine could be up to 90% effective if administered as a half dose followed by a full dose

Topics
AstraZeneca | Coronavirus Vaccine | Serum Institute of India

Reuters  |  PUNE 

By Abhirup Roy and Euan Rocha PUNE (Reuters) - Serum Institute of India, which has partnered with AstraZeneca to manufacture its COVID-19 vaccine, will continue to test a two full dose regimen of the shot despite it showing a lower success rate than a half and full dose regimen in pivotal trials, a top executive told Reuters. The British drugmaker has said its COVID-19 vaccine could be up to 90% effective if administered as a half dose followed by a full dose, but some scientists have questioned the robustness of that result because only a few thousand people were given that ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Tue, December 01 2020. 22:10 IST
RECOMMENDED FOR YOU